Compare AbbVie Inc (ABBV) vs Norwegian Cruise Line Holdings Ltd (NCLH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Norwegian Cruise Line Holdings Ltd — how do they compare? AbbVie Inc trades at $252.5 (market cap $449.91B), while Norwegian Cruise Line Holdings Ltd trades at $18.47 (market cap $8.65B). The key difference: AbbVie Inc is far larger — about 52× Norwegian Cruise Line Holdings Ltd's market cap, and AbbVie Inc pays a 2.72% dividend while Norwegian Cruise Line Holdings Ltd pays none. Which is the better fit depends on your goals.
| ABBV | NCLH | |
|---|---|---|
Market Cap | $449.91B | $8.65B |
Sector | Health | Consumer Cyclical |
52-Week High | $261.07 | $26.94 |
52-Week Low | $184.85 | $14.79 |
Enterprise Value | $513.38B | $23.61B |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.61, down 0.84% on the day, with strong technical momentum showing bullish moving average signals. The company demonstrates solid revenue growth, reaching $61.16B in 2025, though net margins have compressed to 5.79%. Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $2.65 exceeding the $2.59 forecast. Positive clinical trial results for ELAHERE in ovarian cancer and institutional buying activity support investor confidence.
AbbVie presents a favorable risk-reward profile with 68% analyst buy ratings and a $266.33 consensus price target offering 5.4% upside. Key opportunities include Skyrizi/Rinvoq growth offsetting Humira declines, while risks involve patent expirations in the 2030s and margin pressure. The stock's elevated P/E of 124.83 reflects growth expectations but warrants monitoring of execution against guidance.
NCLH trades at $18.83, down 4.8% on the day, reflecting near-term pressure amid a bearish technical signal. The company has demonstrated consistent earnings beats, with Q1 2026 EPS of $0.23 exceeding the $0.15 estimate. Fundamentals show a P/E of 15.53 and a net income margin of 5.66%, while recent news highlights new executive appointments and future cruise itineraries. The stock is trading below the consensus analyst price target of $22.00.
The outlook is mixed; strong earnings performance and a favorable valuation offer upside potential, but high debt levels and a bearish technical trend present significant risks. The stock's performance is closely tied to travel demand and macroeconomic factors affecting the cruise industry.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Norwegian Cruise Line Holdings Ltd
Norwegian Cruise Line is the world's third-largest cruise company by berths (at more than 62,000), operating 29 ships across three brands (Norwegian, Oceania, and Regent Seven Seas), offering both freestyle and luxury cruising. The company has redeployed its entire fleet as of May 2022. With eight passenger vessels on order among its brands through 2027 (representing 20,000 incremental berths), Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sailed to around 500 global destinations before the pandemic.
Read more on NCLH →
